Changes in Informed Consent Policy and Treatment Delays in Stroke Thrombolysis.
Abstract
<h4>Objectives</h4>The efficacy of thrombolytic therapy with tissue plasminogen activator
(tPA) is highly time dependent. Although clinical guidelines do not recommend written
informed consent as it may cause treatment delays, local policy can supersede and
require it. From 2014 to 2017, three out of five public hospitals in Singapore changed
from written to verbal consent at different time points. We aimed to examine the association
of hospital policy changes regarding informed consent on door-to-needle (DTN) times.<h4>Materials
and methods</h4>Using data from the Singapore Stroke Registry and surveys of local
practice, we analyzed data of 915 acute ischemic stroke patients treated with tPA
within 3 hours in all public hospitals between July 2014 to Dec 2017. Patient-level
DTN times before and after policy changes were examined while adjusting for clinical
characteristics, within-hospital clustering, and trends over time.<h4>Results</h4>Patient
characteristics and stroke severity were similar before and after the policy changes.
Overall, the median DTN times decreased from 68 to 53 minutes after the policy changes.
After risk adjustment, changing from written to verbal informed consent was associated
with a 5.6 minutes reduction (95% CI 1.1-10.0) in DTN times. After the policy changed,
the percentage of patients with DTN ≤60 minutes and ≤45 minutes increased from 35.6%
to 66.1% (adjusted OR 1.75; 95% CI 1.12-2.74) and 9.3% to 36.0% (adjusted OR 2.42;
95% CI 1.37-4.25), respectively.<h4>Conclusion</h4>Changing from written to verbal
consent is associated with significant improvement in the timeliness of tPA administration
in acute ischemic stroke.
Type
Journal articleSubject
Informed consentRegistry
Singapore
Stroke
Thrombolysis
Aged
Female
Fibrinolytic Agents
Hospitals, Public
Humans
Informed Consent
Male
Middle Aged
Policy Making
Registries
Retrospective Studies
Singapore
Stroke
Thrombolytic Therapy
Time Factors
Time-to-Treatment
Tissue Plasminogen Activator
Treatment Outcome
Verbal Behavior
Permalink
https://hdl.handle.net/10161/22765Published Version (Please cite this version)
10.1016/j.jstrokecerebrovasdis.2020.105551Publication Info
Xu, Hanzhang; De Silva, Deidre Anne; Woon, Fung Peng; Ong, Marcus Eng Hock; Matchar,
David B; Bettger, Janet Prvu; ... Xian, Ying (2020). Changes in Informed Consent Policy and Treatment Delays in Stroke Thrombolysis. Journal of stroke and cerebrovascular diseases : the official journal of National
Stroke Association, 30(3). pp. 105551. 10.1016/j.jstrokecerebrovasdis.2020.105551. Retrieved from https://hdl.handle.net/10161/22765.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
Janet Prvu Bettger
Adjunct Associate in the Department of Orthopaedic Surgery
Dr. Bettger’s research is dedicated to establishing real world evidence aimed to improve
health care quality and policies that reduce the burden of disease and disability.
As a health services researcher and implementation scientist, her research extends
from observational studies to randomized and pragmatic trials. She was the Founding
Director of Duke Roybal Center for Translational Research in the Behavioral and Social
Sciences of Aging and the Founding Director of Undergraduate
Daniel Todd Laskowitz
Professor of Neurology
Our laboratory uses molecular biology, cell culture, and animal modeling techniques
to examine the CNS response to acute injury. In particular, our laboratory examines
the role of microglial activation and the endogenous CNS inflammatory response in
exacerbating secondary injury following acute brain insult. Much of the in vitro work
in this laboratory is dedicated to elucidating cellular responses to injury with the
ultimate goal of exploring new therapeutic interventions in the clinical settin
David Bruce Matchar
Professor of Medicine
My research relates to clinical practice improvement - from the development of clinical
policies to their implementation in real world clinical settings. Most recently my
major content focus has been cerebrovascular disease. Other major clinical areas in
which I work include the range of disabling neurological conditions, cardiovascular
disease, and cancer prevention. Notable features of my work are: (1) reliance on
analytic strategies such as meta-analysis, simulation, decision analy
Ying Xian
Adjunct Associate Professor in the Department of Neurology
Hanzhang Xu
Assistant Professor in the School of Nursing
Alphabetical list of authors with Scholars@Duke profiles.

Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info